Sign In
Buy JNJ
$239.08
+7.79 (+3.37%)
At Close: Jun 23, 2026
FDA Clears Johnson & Johnson's Darzalex Faspro, Enabling Early Intervention In Myeloma Progression
12:57pm, Friday, 07'th Nov 2025
The U.S. Food and Drug Administration (FDA) approved on Thursday Johnson & Johnson's (NYSE:JNJ) Darzalex Faspro (daratumumab and hyaluronidase-fihj) for a type of blood cancer.
Is a Market Correction Coming? Better Grab 5 of the Safest Dividend Kings Now
08:48am, Friday, 07'th Nov 2025
At 24/7 Wall St., we have focused on dividend stocks for over 15 years because, despite the stock market's ups and downs, many people need solid passive income streams to supplement their income from
Johnson & Johnson: Dividends Don't Lie
05:40am, Friday, 07'th Nov 2025
Johnson & Johnson's latest dividend declaration translates into an annual growth rate of 4.47%. This is the lowest level in at least 10 years, signaling ongoing growth pressures. Mixed Q3 earnings res
DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma
05:07pm, Thursday, 06'th Nov 2025
Phase 3 AQUILA study showed DARZALEX FASPRO® significantly reduced the risk of progression to active multiple myeloma or death by 51 percent compared to active monitoring Landmark approval support
Cramer's Mad Dash: Johnson & Johnson
09:54am, Thursday, 06'th Nov 2025
Jim Cramer breaks down why he's keeping an eye on shares of Johnson & Johnson.
US FDA expands use of J&J's Caplyta as add-on depression drug
07:34am, Thursday, 06'th Nov 2025
The U.S. Food and Drug Administration has approved the expanded use of Johnson & Johnson's drug Caplyta as an add-on treatment for adults with major depressive disorder, the company said on Thursday.
CAPLYTA®, in combination with an oral antidepressant, demonstrated superior efficacy with a favorable safety and tolerability profile consistent with established indications1,2 In pivotal trials, C
Johnson & Johnson to Participate in the Citi's 2025 Global Healthcare Conference
04:50pm, Wednesday, 05'th Nov 2025
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Citi's 2025 Global Healthcare Conference on Wednesday, December 3rd, 2025. Management will participate in a Fire
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Wednesday, 05'th Nov 2025
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Will President Trump's Tylenol Claims Hurt These 2 Leading Pharmaceutical Stocks?
06:15am, Monday, 03'rd Nov 2025
There were rumors that the FDA was going to warn pregnant women against using Tylenol. When the news finally hit, Tylenol maker Kenvue's stock had already fallen a great deal.
Best Dividend Aristocrats For November 2025
10:25am, Saturday, 01'st Nov 2025
The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has underperformed SPY in 2025, with a 6.27% YTD gain versus SPY's 17.8%. Despite overall underperformance, select Aristocrats like CAT, CAH, CHRW
Here's Why Johnson & Johnson (JNJ) is a Strong Value Stock
10:42am, Thursday, 30'th Oct 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The EPIC study will evaluate treatment with IMAAVY™ versus efgartigimod in adults with gMG and will include a treatment-switch arm The Company also announced new data from the pivotal Vibrance-MG st
Levin Papantonio Announces Jury Awards $20 Million Verdict in Talc Mesothelioma Case Casaretto Estate v. Johnson & Johnson
06:15pm, Tuesday, 28'th Oct 2025
FORT LAUDERDALE, Fla., Oct. 28, 2025 (GLOBE NEWSWIRE) -- A jury today awarded $20 million to the family of Dr. Alberto A.
J&J Stock Can Fall
09:25am, Tuesday, 28'th Oct 2025
Johnson & Johnson (JNJ) is currently encountering challenges. Even the largest corporations are not invulnerable.
